SCHEMBL5544539

SCHEMBL5544539

[CH2]CNc1ccccc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.56
MAPT P10636 5/20 0.48
ALDH1A1 P00352 5/20 0.48
NPC1 O15118 1/20 0.48
GAA P10253 1/20 0.48
RAB9A P51151 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA4 P22748 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
L3MBTL1 Q9Y468 4/20 0.46
MAPK1 P28482 2/20 0.46
POLB P06746 2/20 0.45
KDM4E B2RXH2 1/20 0.45
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28039658 0.85 HTR7 (0.45) CHRM2MAPTALDH1A1NPC1GAA
SCHEMBL10632588 0.83 CHRM2 (0.59) CHRM2MAPTALDH1A1NPC1GAA
SCHEMBL30994802 0.81 CHRM2 (0.58) CHRM2MAPTALDH1A1NPC1GAA
SCHEMBL1022424 0.81 CHRM2 (0.58) CHRM2MAPTALDH1A1NPC1GAA
SCHEMBL360495 0.80 CA12 (0.55) CHRM2MAPTALDH1A1NPC1GAA
SCHEMBL25085547 0.79 CHRM2 (0.56) CHRM2MAPTALDH1A1NPC1GAA
SCHEMBL28079809 0.79 CHRM2 (0.56) CHRM2MAPTALDH1A1NPC1GAA
SCHEMBL10201681 0.79 CHRM2 (0.56) CHRM2MAPTALDH1A1NPC1GAA
Hydrochloric Acid SCHEMBL27890009 0.79 CHRM2 (0.61) CHRM2MAPTALDH1A1NPC1GAA
SCHEMBL8631283 0.79 CHRM2 (0.51) CHRM2MAPTALDH1A1NPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CHRM2 862/4885MAPT 4117/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.